Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban

Rivaroxaban, a direct factor Xa inhibitor, is widely used to reduce the chance of stroke in patients with atrial fibrillation (AF). It is not clear why the prothrombin time (PT) of the international normalized ratio (INR) fails to correlate with treatment using rivaroxaban in patients with AF. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jen-Hung, Lin, Yung-Kuo, Chung, Cheng-Chih, Hsieh, Ming-Hsiung, Chiu, Wan-Chun, Chen, Yi-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714846/
https://www.ncbi.nlm.nih.gov/pubmed/30244598
http://dx.doi.org/10.1177/1076029618800830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714846/
https://www.ncbi.nlm.nih.gov/pubmed/30244598
http://dx.doi.org/10.1177/1076029618800830

Ejemplares similares